RAF1 and neoplasm: Structural and functional analyses have indicated that MEK inhibitors with superior anti-tumor activity in KRAS-driven tumors form a strong hydrogen-bond interaction with the backbone amide of S212 in MEK that is critical for blocking MEK feedback phosphorylation by wild-type RAF [32].